Nexalin Technology EPS NXL
Diluted earnings per share by quarter and over the last twelve months, from 2021.
- Last 12 months, to Jun 30, 2026
- −$14.40
- Latest quarter, Q2 FY26
- −$3.30
- Fiscal year 2025
- −$15.30
Nexalin Technology's earnings per share was −$14.40 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$3.30.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$15.30 | n/a |
| FY2024 | −$24.00 | n/a |
| FY2023 | −$18.60 | n/a |
| FY2022 | −$9.00 | n/a |
| FY2021 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$3.30 | n/a | −$14.40 | |
| Q1 FY26 | −$3.30 | n/a | −$14.10 | |
| Q4 FY25 | −$3.90 | n/a | −$15.30 | |
| Q3 FY25 | −$3.90 | n/a | −$19.20 | |
| Q2 FY25 | −$3.00 | n/a | −$22.20 | |
| Q1 FY25 | −$4.50 | n/a | −$24.30 | |
| Q4 FY24 | −$7.80 | n/a | −$24.00 | |
| Q3 FY24 | −$6.90 | n/a | −$19.20 | |
| Q2 FY24 | −$5.10 | n/a | −$21.60 | |
| Q1 FY24 | −$4.20 | n/a | −$19.80 | |
| Q4 FY23 | −$3.00 | n/a | −$18.60 | |
| Q3 FY23 | −$9.30 | n/a | −$18.60 |
Against its peers
Companies in Medical - Devices nearest Nexalin Technology's size, closest first, today.
| Company | EPS, 12 months |
|---|---|
| NXLNexalin Technology | −$14.40 |
| NUWENuwellis | −$1228.86 |
| NDRAENDRA Life Sciences | −$5.99 |
| IRIXIridex | −$0.20 |
| QTIQT Imaging | −$1.57 |
| POCIPrecision Optics | −$0.46 |
| ECORelectroCore | −$1.66 |
| OMOutset Medical | −$4.08 |
| HYPRHyperfine | −$0.38 |
| NRXSNeuraxis, INC | −$0.79 |
| STXSStereotaxis | −$0.24 |
| Peer median | −$1.18 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Nexalin Technology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.